Abstract: A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.

Abstract: A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.

Abstract: Disclosed herein are a method and apparatus for transmitting an 8K Scalable High Efficiency Video Coding (SHVC) service based on broadcast network interconnection. The method includes defining signaling information for the 8K SHVC service, and delivering the defined signaling information to a MPEG Media Transport (MMT)/Real time Object delivery Over Unidirectional Transport (ROUTE) packetizer or to a gateway, separating 8K content into a base layer compatible with a broadcast network and an enhancement layer compatible with a communication network, delivering the base layer from the MMT/ROUTE packetizer to a receiver through the gateway and a transmitter, and delivering the enhancement layer to the receiver through a Dynamic Adaptive Streaming over HTTP (DASH) server.

Abstract: A liquefied gas storage tank includes a corner block disposed on a corner portion, wherein the corner block includes a lower block, an upper block and an upper connecting block, the upper block includes a first inner fixing unit and a second inner fixing unit respectively provided inside a first surface and a second surface, bonded and connected to a secondary barrier, and each having a structure in which a primary inner plywood, a primary corner insulating material, and a primary outer plywood are stacked, and an inner bent portion installed at a corner spatial portion between the first inner fixing unit and the second inner fixing unit, and both side surfaces of the inner bent portion that are perpendicular to the secondary barrier each have a height reduced from a total height of each of the first and second inner fixing units.

Abstract: A display device includes a first display area including a first pixel area; a second display area including a second pixel area and a transmissive area; a signal line, a common electrode, and a touch electrode that are disposed in the second display area. The common electrode includes an opening overlapping the transmissive area, and the common electrode is disposed between the signal line and the touch electrode to overlap the signal line.

Abstract: The liquefied gas storage tank includes a primary barrier, a primary insulation wall, a secondary barrier, and a secondary insulation wall. In a state where unit elements are arranged adjacent to each other, each of the unit elements being formed by stacking the secondary insulation wall, the secondary barrier, and a fixed insulation wall which is a part of the primary insulation wall, the primary insulation wall may comprise: a connection insulation wall provided in the space between the adjacent fixed insulation walls; first slits formed between the fixed insulation walls and the connection insulation wall when the connection insulation wall is inserted and installed between the adjacent fixed insulation walls; a plurality of second slits formed in a lengthwise direction and a widthwise direction of the fixed insulation walls; and a first insulating filler material for filling the first slits.

Abstract: A positive electrode active material for use in a positive electrode of a lithium-sulfur battery is provided. The positive electrode active material includes a) particles A having a first porous carbon material, at least part of which is crystalline, and catalyst particles deposited on the first porous carbon material; and b) particles B having a second porous carbon material, at least part of which is crystalline, and sulfur infiltrated into the second porous carbon material, wherein the particles A and the particles B have different morphologies.

Abstract: A carbon composite for an electrode of a battery, a battery including the same, and a method of manufacturing the same are provided. The carbon composite comprises a porous carbon material, and vanadium nitride particles formed on a surface of the porous carbon material, and provides improved performance of the battery including the same. The method of manufacturing the same is capable of preparing catalyst particles uniformly distributed on the surface of the porous carbon material without using harmful gas or strong acid.

Abstract: The extract of a mixture of cinnamon twig and moutan root bark, cinnamon twig and peony root, or cinnamon twig and poria according to the present invention has been confirmed to inhibit the excessive generation of advanced glycation end-products, which occurs under chronic diabetic conditions, exhibit the effect of fragmentizing a cross-link between the advanced glycation end-products and matrix proteins, have an excellent effect in inhibiting the generation of the advanced glycation end-products in a human retinal pigment epithelial cell line subjected to a hyperglycemic or aging environment, and have excellent effects in delaying, preventing, and treating diabetic complications, muscular degeneration, commotio retinae, and lower extremity edema in various animal models of diabetic complications, macular degeneration, and lower extremity edema, and thus the mixture extract can effectively be used as an active ingredient for a composition for preventing and treating diabetic complications, including diabetic

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which may cause macular degeneration, inhibits blood-retinal barrier breakdown causing retinal edema in various animal models, protects or treats a subretinal region causing dry macular degeneration, inhibits angiogenesis causing wet macular degeneration, and thus can be usefully used as an active ingredient for the composition for preventing and treating angioedema including macular degeneration, macular edema, retinal edema, or varicose veins.

Abstract: A method of providing a card game implemented by a computer includes the steps of; determining open cards and hidden cards different from one another to be assigned to first and second user terminals each including a screen configured to display an open card area having rows and columns and a hidden card area; providing a first card identifier information of the open cards, a first location information of the open cards, a second card identifier information of the hidden cards, and a second location information of the hidden cards; determining a rating of cards disposed along each column of the open card area based on a combination of the cards in the same column; comparing the rating of each column of the first user terminal to that of the second user terminal; and determining win or lose of the card game based on the compared result for each column.

Abstract: A method of providing a card game implemented by a computer includes the steps of; determining open cards and hidden cards different from one another to be assigned to first and second user terminals each including a screen configured to display an open card area having rows and columns and a hidden card area; providing a first card identifier information of the open cards, a first location information of the open cards, a second card identifier information of the hidden cards, and a second location information of the hidden cards; determining a rating of cards disposed along each column of the open card area based on a combination of the cards in the same column; comparing the rating of each column of the first user terminal to that of the second user terminal; and determining win or lose of the card game based on the compared result for each column.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which may cause macular degeneration, inhibits blood-retinal barrier breakdown causing retinal edema in various animal models, protects or treats a subretinal region causing dry macular degeneration, inhibits angiogenesis causing wet macular degeneration, and thus can be usefully used as an active ingredient for the composition for preventing and treating angioedema including macular degeneration, macular edema, retinal edema, or varicose veins.

Abstract: The extract of a mixture of cinnamon twig and moutan root bark, cinnamon twig and peony root, or cinnamon twig and poria according to the present invention has been confirmed to inhibit the excessive generation of advanced glycation end-products, which occurs under chronic diabetic conditions, exhibit the effect of fragmentizing a cross-link between the advanced glycation end-products and matrix proteins, have an excellent effect in inhibiting the generation of the advanced glycation end-products in a human retinal pigment epithelial cell line subjected to a hyperglycemic or aging environment, and have excellent effects in delaying, preventing, and treating diabetic complications, muscular degeneration, commotio retinae, and lower extremity edema in various animal models of diabetic complications, macular degeneration, and lower extremity edema, and thus the mixture extract can effectively be used as an active ingredient for a composition for preventing and treating diabetic complications, including diabetic

Abstract: The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity.

Abstract: The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.